Neuroendocrine Tumors Clinical Trials

64 recruiting

Neuroendocrine Tumors Trials at a Glance

79 actively recruiting trials for neuroendocrine tumors are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 34 trials, with the heaviest enrollment activity in Bethesda, Philadelphia, and Milan. Lead sponsors running neuroendocrine tumors studies include National Cancer Institute (NCI), Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and Barbara Ann Karmanos Cancer Institute.

Browse neuroendocrine tumors trials by phase

Treatments under study

About Neuroendocrine Tumors Clinical Trials

Looking for clinical trials for Neuroendocrine Tumors? There are currently 64 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroendocrine Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroendocrine Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 79 trials

Recruiting

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Neuroendocrine Tumors
Ipsen150 enrolled28 locationsNCT07314164
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 1

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Neuroendocrine TumorsNeuroendocrine Carcinoma
Peter Hosein, MD36 enrolled1 locationNCT06889493
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Not Applicable

Nutrition Intervention for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neuroendocrine Tumors (pNET)
Children's Hospital of Philadelphia18 enrolled2 locationsNCT07554560
Recruiting
Phase 2Phase 3

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Phase 2

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)740 enrolled1 locationNCT04074135
Recruiting
Phase 1Phase 2

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Hepatocellular CarcinomaNeuroendocrine TumorsGastrointestinal Cancer Metastatic
Teclison Ltd.25 enrolled2 locationsNCT02174549
Recruiting
Not Applicable

Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

Endoscopic Ultrasound-Guided Radiofrequency AblationPancreatic Neuroendocrine Tumors (pNET)Pancreatic Cystic Neoplasms
Institute for Clinical and Experimental Medicine50 enrolled1 locationNCT07536087
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1Phase 2

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan49 enrolled11 locationsNCT05048901
Recruiting
Phase 1Phase 2

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 1

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 2

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI)45 enrolled1 locationNCT06228066
Recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation

Neuroendocrine TumorsMEN1 Mutation
Centre Hospitalier Universitaire Dijon297 enrolled1 locationNCT06430021
Recruiting
Phase 1

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine TumorsSomatostatin Receptor-positive Neuroendocrine Tumor
University of Wisconsin, Madison10 enrolled1 locationNCT06122610
Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System50 enrolled2 locationsNCT04090034
Recruiting
Phase 2

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

Carcinoma, Small CellNeuroendocrine TumorsGastrointestinal Stromal Tumors+11 more
Centre Oscar Lambret88 enrolled3 locationsNCT05500391